Dramatic resolution of disseminated pyoderma gangrenosum associated with monoclonal gammopathy after therapy with bortezomib and dexamethasone.
Pyoderma gangrenosum (PG) is an uncommon inflammatory and ulcerative skin disorder, which is commonly associated with systemic conditions such as inflammatory bowel disease, arthritis and haematological malignancies. It is widely stated that control of the underlying diseases may lead to resolution...
| Publicado en: | International Wound Journal Vol. 14; no. 6; pp. 1382 - 1385 |
|---|---|
| Autores principales: | , , , , , |
| Formato: | case study pictorial Journal Article |
| Publicado: |
Wiley-Blackwell
Dec2017
|
| Acceso en línea: | Ver este registro en EBSCOhost |
| fields | @attributes: recordID: 1 pdfLink: plink: https://search.ebscohost.com/login.aspx?direct=true&db=ccm&AN=126440955&site=ehost-live header: @attributes: shortDbName: ccm uiTerm: 126440955 longDbName: CINAHL Complete uiTag: AN controlInfo: bkinfo: dissinfo: jinfo: jid: 17424801 1725 jtl: International Wound Journal issn: 17424801 maglogo: Y pubinfo: dt: Dec2017 vid: 14 iid: 6 pid: 480 pub: Wiley-Blackwell place: Malden, Massachusetts artinfo: ui: 126440955 126440955 126440955 10.1111/iwj.12746 126440955 ppf: 1382 ppct: 3 formats: tig: atl: Dramatic resolution of disseminated pyoderma gangrenosum associated with monoclonal gammopathy after therapy with bortezomib and dexamethasone. aug: au: Velasco‐Tamariz, Virginia Carreño‐Tarragona, Gonzalo Tous‐Romero, Fátima Gil‐de la Cruz, Elena Martín‐Clavero, Estela Rivera‐Díaz, Raquel affil: Department of Dermatology, Hospital 12 de Octubre, Madrid Spain sug: subj: Pyoderma Gangrenosum Monoclonal Gammopathy of Undetermined Significance Bortezomib Therapeutic Use Dexamethasone Therapeutic Use Multiple Myeloma Sweet's Syndrome Female Adult Tumor Necrosis Factor Adult: 19-44 years Female ab: Pyoderma gangrenosum (PG) is an uncommon inflammatory and ulcerative skin disorder, which is commonly associated with systemic conditions such as inflammatory bowel disease, arthritis and haematological malignancies. It is widely stated that control of the underlying diseases may lead to resolution of PG. However, standard of care dictates that patients suffering with monoclonal gammopathy of undetermined significance or smouldering multiple myeloma (MM) should not receive therapy unless they progress to symptomatic MM. Here, we report a woman in her 40s with a disseminated corticodependent PG, resistant to any treatment attempted, including anti-tumoral necrosis factor (TNF) therapy in which bortezomib-dexamethasone regimen results in dramatic healing of all lesions in only a month. This case supports the belief that treatment of the underlying monoclonal gammopathy could be necessary when PG presents as an aggressive, non-responding skin disease. pubtype: Academic Journal doctype: case study pictorial Journal Article ougenre: Article language: English refInfo: holdings: @attributes: islocal: N |
|---|